Table 1 Summary of demographic data and baseline characteristics
Parameter | ABP 710 (n = 279) | Infliximab RP (n = 279) | Total (n = 558) |
|---|---|---|---|
Mean age, years (range) | 55.0 (23, 77) | 54.8 (19, 77) | 54.9 (19, 77) |
Women, n (%) | 214 (76.7) | 223 (79.9) | 437 (78.3) |
Ethnicity, n (%) | |||
Hispanic or Latino | 18 (6.5) | 13 (4.7) | 31 (5.6) |
Not Hispanic or Latino | 261 (93.5) | 266 (95.3) | 527 (94.4) |
Race, n (%) | |||
White | 265 (95.0) | 267 (95.7) | 532 (95.3) |
Black or African American | 12 (4.3) | 12 (4.3) | 24 (4.3) |
Asian | 2 (0.7) | 0 (0.0) | 2 (0.4) |
Region, n (%) | |||
Asia Pacific | 5 (1.8) | 4 (1.4) | 9 (1.6) |
Europe | 220 (78.9) | 222 (79.6) | 442 (79.2) |
North America | 54 (19.4) | 53 (19.0) | 107 (19.2) |
Mean duration of RA, years (range) | 8.72 (0.3, 45.0) | 8.34 (0.3, 39.0) | 8.53 (0.3, 45.0) |
Duration of RA category, n (%) | |||
< 5 years | 104 (37.3) | 123 (44.1) | 227 (40.7) |
≥ 5 years | 175 (62.7) | 156 (55.9) | 331 (59.3) |
Swollen joint count, mean (SD) | 14.6 (8.05) | 14.7 (8.83) | 14.7 (8.44) |
Tender joint count, mean (SD) | 23.1 (12.16) | 23.8 (13.38) | 23.4 (12.78) |
Subject Global Health Assessment, mean (SD) | 65.4 (18.13) | 64.1 (20.03) | 64.7 (19.10) |
Investigator Global Health Assessment, mean (SD) | 64.5 (15.88) | 64.1 (15.76) | 64.3 (15.81) |
HAQ-DI, mean (SD) | 1.44 (0.584) | 1.42 (0.617) | 1.43 (0.601) |
Serum CRP, mean (SD), mg/L | 14.26 (20.171) | 14.64 (23.117) | 14.45 (21.675) |
DAS28-CRP, mean (SD) | 5.58 (0.912) | 5.60 (0.893) | 5.59 (0.902) |
RF status, n (%) | |||
Positive at screening | 244 (87.5) | 251 (90.0) | 495 (88.7) |
Anti-CCP status, n (%) | |||
Positive at screening | 253 (90.7) | 253 (90.7) | 506 (90.7) |
Prior biologic use for RA, n (%) | 77 (27.6) | 81 (29.0) | 158 (28.3) |
MTX dose, mean (SD), mg/week | 17.54 (4.835) | 17.19 (4.938) | 17.36 (4.886) |